Meclozine

Thông tin thuốc gốc
Chỉ định và Liều dùng
Oral
Vertigo
Adult: For cases associated with diseases affecting the vestibular system: 25-100 mg daily in divided doses, based on clinical response. Treatment and dosing recommendations may vary among individual products and between countries (refer to specific product guidelines).

Oral
Motion sickness
Adult: As prevention and treatment of nausea, vomiting or dizziness associated with motion sickness: 25-50 mg given the night before or approx 1 hour before travelling; may repeat dose 24 hourly if needed. Treatment and dosing recommendations may vary among individual products and between countries (refer to specific product guidelines).
Child: 2-5 years 6.25 mg once daily; 6-12 years 12.5 mg once daily; >12 years Same as adult dose. All doses may be given the night before or approx 1 hour before travelling; may repeat dose 24 hourly if needed. Treatment and dosing recommendations may vary among individual products and between countries (refer to specific product guidelines).
Nhóm bệnh nhân đặc biệt
Pharmacogenomics:

CYP2D6 is the dominant metabolising enzyme of meclozine. Based on the annotation of the US Food and Drug Administration (US FDA) drug label for meclizine, the genetic polymorphism of CYP2D6 gene which results in poor-, intermediate-, extensive-, and ultrarapid metaboliser phenotypes may contribute to the larger inter-individual variability in meclizine exposure. Therefore, it is recommended to monitor for adverse reactions and clinical effects accordingly in patients with CYP2D6 polymorphism.
Cách dùng
May be taken with or without food.
Thận trọng
Patient with asthma, narrow-angle glaucoma, prostatic hyperplasia, bladder neck obstruction, urinary stricture, pyloric or duodenal obstruction. Patients with CYP2D6 polymorphism. Renal and hepatic impairment. Children and elderly. Pregnancy and lactation.
Tác dụng không mong muốn
Significant: Anticholinergic effects (e.g. blurred vision, urinary retention, xerostomia), CNS effects (e.g. drowsiness, memory impairment, dementia).
Gastrointestinal disorders: Vomiting.
General disorders and administration site conditions: Fatigue.
Immune system disorders: Anaphylaxis.
Nervous system disorders: Headache.
Thông tin tư vấn bệnh nhân
This drug may cause drowsiness, if affected, do not drive or operate machinery.
Chỉ số theo dõi
Monitor mental alertness.
Tương tác
Enhanced CNS depression with other CNS depressants (e.g. barbiturates). Prolonged and enhanced anticholinergic effects with MAOIs.
Tương tác với thức ăn
May enhance the CNS depressant effect of alcohol.
Tác dụng
Description:
Mechanism of Action: Meclozine, a piperazine derivative, inhibits vestibular end-organ receptors and prevents activation of central cholinergic pathways.
Synonym(s): Meclizine.
Onset: Approx 1 hour.
Duration: Approx 24 hours.
Pharmacokinetics:
Absorption: Readily absorbed from the gastrointestinal tract. Time to peak plasma concentration: 3.1 ± 1.4 hours.
Distribution: Volume of distribution: 7 L/kg.
Metabolism: Metabolised in the liver into norchlorcyclizine.
Excretion: Via urine and faeces as unchanged drug and metabolites. Elimination half-life: Approx 5-6 hours.
Đặc tính

Chemical Structure Image
Meclozine

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 4034, Meclizine. https://pubchem.ncbi.nlm.nih.gov/compound/Meclizine. Accessed Apr. 25, 2024.

Bảo quản
Store between 20-25°C.
Phân loại MIMS
Thuốc chống nôn / Thuốc trị chóng mặt
Phân loại ATC
R06AE05 - meclozine ; Belongs to the class of piperazine derivatives used as systemic antihistamines.
Tài liệu tham khảo
Annotation of FDA Label for Meclizine and CYP2D6. Pharmacogenomics Knowledgebase (PharmGKB). https://www.pharmgkb.org. Accessed 20/03/2024.

Anon. Meclizine. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 20/03/2024.

Antivert Tablet; Tablet, Chewable (Casper Pharma LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 20/03/2024.

Bonamine (Taisho Pharmaceuticals [Philippines], Inc). MIMS Philippines. http://www.mims.com/philippines. Accessed 21/03/2024.

Buckingham R (ed). Meclozine Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 21/03/2024.

CYP2D6 - Meclizine. UpToDate Lexidrug, Pharmacogenomics Online. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 23/04/2024.

Meclizine 25 Tablet (The Generic Pharmaceutical Company). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 23/04/2024.

Meclizine. Gold Standard Drug Database in ClinicalKey [online]. Elsevier Inc. https://www.clinicalkey.com. Accessed 21/03/2024.

Meclozine [Meclizine]. UpToDate Lexidrug, Lexi-Drugs Multinational Online. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 23/04/2024.

Sea-Legs Tablets (G R Lane Health Products Ltd.). MHRA. https://products.mhra.gov.uk. Accessed 20/03/2024.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Meclozine từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2026 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com